Menu
Search
|

Menu

Close
X

Neovasc Inc NVCN.OQ (NASDAQ Stock Exchange Capital Market)

1.41 USD
-0.05 (-3.42%)
As of Nov 16
chart
Previous Close 1.46
Open 1.49
Volume 44,253
3m Avg Volume 148,356
Today’s High 1.49
Today’s Low 1.40
52 Week High 97.86
52 Week Low 1.39
Shares Outstanding (mil) 19.46
Market Capitalization (mil) 48.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
5
FY16
10
FY15
10
EPS (USD)
FY18
-42.245
FY17
-28.307
FY16
-131.355
FY15
-40.725
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
10.84
20.58
Price to Book (MRQ)
vs sector
--
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
--
13.83
LT Debt to Equity (MRQ)
vs sector
--
9.93
Return on Investment (TTM)
vs sector
--
13.58
Return on Equity (TTM)
vs sector
--
15.11

EXECUTIVE LEADERSHIP

Steven Rubin
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Fred Colen
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Christopher Clark
Chief Financial Officer, Corporate Secretary, Since 2015
Salary: $278,500.00
Bonus: --
Brian McPherson
Chief Operating Officer, Since 2009
Salary: $221,500.00
Bonus: --
Vicki Bebeau
Vice President - Clinical Affairs, Since 2014
Salary: $161,993.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

5138-13562 Maycrest Way
RICHMOND   BC   V6V 2J7

Phone: +1604.2704344

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

SPONSORED STORIES